Clinical Trial

International Pilot Study for Dual Non-invasive Assesment of Embryo Development

Study acronym: PANDORA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Choosing the best embryo is one of the major challenges for achieving success in in vitro fertilization (IVF). Traditionally, embryo evaluation has been based on morphological quality (how the embryo looks like) and chromosomal status as diagnosed by a genetic testing. However, recently new techniques that do not require manipulation of the embryo have been developed and have shown promising results. The goal of this observational study is, by combining two non-invasive techniques, to find out some parameters during embryo development which may be related with the embryo's chromosomic status. For that, infertile women planning to undergo an IVF/ICSI treatment with a recommended niPGT-A (non-invasive Preimplantation Genetic Testing for Aneuploidies) will be invited to join the study. The main question it aims to answer is: * Can morphokinetics parameters correlate with embryo chromosomal status? Participants will follow their previously programmed IVF/ICSI treatment and no additional visits/interventions will be required by their participation in the study. The obtained embryos will be cultured in a time-lapse system instead of in a conventional incubator, and niPGT-A will be performed. Following the standard practice, a deferred single embryo transfer (SET) will be performed according to the niPGT-A results. After the transfer, patients will be followed-up as usual.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-23; most recent amendment 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2024-12-26
Trial Details
NCT Number NCT06524648
Lead Sponsor Igenomix
Conditions Infertility
Enrollment 200 participants
Start Date 2024-10-29
Primary Completion 2026-02 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-01